Another paper was published detailing the implementation process of the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study, the first and only randomized clinical trial on UVC disinfection. The report, Implementation Lessons Learned From the Benefits of Enhanced Terminal Room (BETR) Disinfection Study: Process and Perceptions of Enhanced Disinfection with Ultraviolet Disinfection Devices,

Next in our BETR-D series, another analysis of the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study showed that enhanced disinfection using UVC leads to a reduction of microbial contamination and a decrease in patient colonization and infection. The substudy, Enhanced disinfection leads to reduction of microbial contamination and a decrease in

Tru-D SmartUVC, a leader in the UVC disinfection space, will attend and exhibit at the 2019 AHE Exchange, August 21-24 in San Antonio, Texas. Tru-D invites attendees to its booth #307 to learn how the UVC disinfection robot can help prevent hospital-acquired infections and provide a cleaner health care environment.

Using the same data as the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study, researchers did a secondary analysis of the BETR-D study, which showed that enhanced terminal room disinfection with Tru-D SmartUVC can lead to a decrease in the incidence of targeted multidrug-resistant organisms (MDROs) such as C. diff and VRE

In the hierarchy of scientific studies, randomized clinical trials are some of the most highly-regarded. Until 2017, there had not been a randomized control trial on UVC disinfection in the health care setting. The Benefits of Enhanced Terminal-Room Disinfection study, or BETR-D study, was the first to examine UVC disinfection